These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 24722392

  • 1. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS, Muñoz BE, Mkocha H, Gaydos CA, Quinn TC, West SK.
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [Abstract] [Full Text] [Related]

  • 2. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, West SK, Bailey RL, Porco TC, Keenan JD, Lietman TM, Oldenburg CE.
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [Abstract] [Full Text] [Related]

  • 3. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, Emerson PM, Callahan K, Cotter SY, Stoller NE, Porco TC, Oldenburg CE, Lietman TM.
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [Abstract] [Full Text] [Related]

  • 4. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, Laye M, Makalo P, Manjang A, Molina S, Sarr-Sissoho I, Quinn TC, Lietman T, Holland MJ, Mabey D, West SK, Bailey R, Partnership for Rapid Elimination of Trachoma (PRET) study group.
    PLoS Negl Trop Dis; 2013 Aug; 7(6):e2115. PubMed ID: 23785525
    [Abstract] [Full Text] [Related]

  • 5. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK.
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [Abstract] [Full Text] [Related]

  • 6. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J, He B, Wang J, Greene G, Schein Y, Mkocha H, Munoz B, Quinn TC, Gaydos C, West SK.
    Invest Ophthalmol Vis Sci; 2014 Jun 06; 55(7):4144-50. PubMed ID: 24906862
    [Abstract] [Full Text] [Related]

  • 7. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H, Ramadhani AM, Massae P, Mafuru E, Malisa A, Mbuya K, Makupa W, Mtuy T, Derrick T, Houghton J, Bailey RL, Mabey DCW, Burton MJ, Holland MJ.
    Front Public Health; 2022 Jun 06; 10():1015714. PubMed ID: 36324475
    [Abstract] [Full Text] [Related]

  • 8. Can corneal pannus with trachomatous inflammation--follicular be used in combination as an improved specific clinical sign for current ocular Chlamydia trachomatis infection?
    Derrick T, Holland MJ, Cassama E, Markham-David R, Nabicassa M, Marks M, Bailey RL, Last AR.
    Parasit Vectors; 2016 Jan 27; 9():30. PubMed ID: 26812948
    [Abstract] [Full Text] [Related]

  • 9. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study.
    Harding-Esch E, Jofre-Bonet M, Dhanjal JK, Burr S, Edwards T, Holland M, Sillah A, West S, Lietman T, Keenan J, Mabey D, Bailey R.
    PLoS Negl Trop Dis; 2015 Apr 27; 9(4):e0003670. PubMed ID: 25901349
    [Abstract] [Full Text] [Related]

  • 10. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK, Munoz BE, Mkocha H, Gaydos C, Quinn T.
    Ophthalmic Epidemiol; 2015 Apr 27; 22(3):170-5. PubMed ID: 26158574
    [Abstract] [Full Text] [Related]

  • 11. Serology, infection, and clinical trachoma as tools in prevalence surveys for re-emergence of trachoma in a formerly hyperendemic district.
    Odonkor M, Naufal F, Munoz B, Mkocha H, Kasubi M, Wolle M, West S.
    PLoS Negl Trop Dis; 2021 Apr 27; 15(4):e0009343. PubMed ID: 33861754
    [Abstract] [Full Text] [Related]

  • 12. Cohort and age effects of mass drug administration on prevalence of trachoma: a longitudinal study in rural Tanzania.
    Shekhawat N, Mkocha H, Munoz B, Gaydos C, Dize L, Quinn TC, West SK.
    Invest Ophthalmol Vis Sci; 2014 Apr 11; 55(4):2307-14. PubMed ID: 24448262
    [Abstract] [Full Text] [Related]

  • 13. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia.
    Burr SE, Hart JD, Edwards T, Baldeh I, Bojang E, Harding-Esch EM, Holland MJ, Lietman TM, West SK, Mabey DC, Sillah A, Bailey RL.
    PLoS Negl Trop Dis; 2013 Apr 11; 7(7):e2347. PubMed ID: 23936573
    [Abstract] [Full Text] [Related]

  • 14. Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
    Burr SE, Hart J, Samikwa L, Chaima D, Cooley G, Martin D, Masika M, Solomon AW, Bailey RL, Kalua K.
    PLoS Negl Trop Dis; 2019 Oct 11; 13(10):e0007749. PubMed ID: 31658258
    [Abstract] [Full Text] [Related]

  • 15. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM, Derrick T, Macleod D, Massae P, Malisa A, Mbuya K, Mtuy T, Makupa W, Roberts CH, Bailey RL, Mabey DCW, Holland MJ, Burton MJ.
    PLoS Negl Trop Dis; 2019 Jul 11; 13(7):e0007559. PubMed ID: 31306419
    [Abstract] [Full Text] [Related]

  • 16. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM, Holland MJ, Schémann JF, Sillah A, Sarr B, Christerson L, Pickering H, Molina-Gonzalez S, Sarr I, Andreasen AA, Jeffries D, Grundy C, Mabey DCW, Herrmann B, Bailey RL.
    Parasit Vectors; 2019 Oct 22; 12(1):497. PubMed ID: 31640755
    [Abstract] [Full Text] [Related]

  • 17. Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program.
    Pant BP, Bhatta RC, Chaudhary JS, Awasthi S, Mishra S, Sharma S, Cuddapah PA, Gwyn SE, Stoller NE, Martin DL, Keenan JD, Lietman TM, Gaynor BD.
    PLoS Negl Trop Dis; 2016 Feb 22; 10(2):e0004462. PubMed ID: 26871898
    [Abstract] [Full Text] [Related]

  • 18. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H, Landskroner E, Amza A, Aragie S, Godwin WW, de Hostos Barth A, O'Brien KS, Lietman TM, Oldenburg CE.
    PLoS Negl Trop Dis; 2021 Jul 22; 15(7):e0009491. PubMed ID: 34237074
    [Abstract] [Full Text] [Related]

  • 19. Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial.
    Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, Burr SE, Sillah A, Gaydos CA, Stare D, Mabey DC, Bailey RL, West SK, PRET Partnership.
    PLoS Negl Trop Dis; 2010 Nov 02; 4(11):e861. PubMed ID: 21072224
    [Abstract] [Full Text] [Related]

  • 20. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
    Gower EW, Solomon AW, Burton MJ, Aguirre A, Muñoz B, Bailey R, Holland M, Makalo P, Massae P, Mkocha H, Mabey DC, West SK.
    Invest Ophthalmol Vis Sci; 2006 Nov 02; 47(11):4767-71. PubMed ID: 17065486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.